



(11) **EP 3 464 292 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73
- (48) Corrigendum issued on:
26.10.2022 Bulletin 2022/43
- (45) Date of publication and mention of the grant of the patent:
21.09.2022 Bulletin 2022/38
- (21) Application number: **17730638.8**
- (22) Date of filing: **05.06.2017**
- (51) International Patent Classification (IPC):
C07D 491/107^(2006.01) A61K 31/4355^(2006.01)
A61P 9/00^(2006.01)
- (52) Cooperative Patent Classification (CPC):
C07D 491/107; A61K 45/06; A61P 9/10;
A61K 31/4525
- (86) International application number:
PCT/US2017/035867
- (87) International publication number:
WO 2017/214002 (14.12.2017 Gazette 2017/50)

(54) **MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO**

MODULATOREN DES BETA-3-ADRENERGEN REZEPTORS DIE SICH FÜR DIE BEHANDLUNG ODER PRÄVENTION VON DAMIT IN ZUSAMMENHANG STEHENDEN ERKRANKUNGEN EIGNEN

MODULATEURS DU RÉCEPTEUR ADRÉNERGIQUE-BÊTA-3 UTILES POUR LE TRAITEMENT ET LA PREVENTION DE TROUBLES ASSOCIES A CE DERNIER

- (84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD
- (30) Priority: **06.06.2016 US 201662346293 P**
- (43) Date of publication of application:
10.04.2019 Bulletin 2019/15
- (73) Proprietor: **Arena Pharmaceuticals, Inc.**
New York, NY 10017 (US)
- (72) Inventors:
 - **TRAN, Thuy-Anh**
San Diego
California 92130 (US)
- **DO, Quyen-Quyen**
San Diego
California 92127 (US)
- **ULLMAN, Brett**
San Diego
California 92105 (US)
- **BLACKBURN, Anthony C.**
San Diego, CA 92128 (US)
- **NAGURA, Maiko**
La Jolia, CA 92037 (US)
- (74) Representative: **Mewburn Ellis LLP**
Aurora Building
Counterslip
Bristol BS1 6BX (GB)
- (56) References cited:
WO-A1-01/43744 WO-A1-99/65895
WO-A1-2010/058318 WO-A2-2006/060122

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 464 292 B8